Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.

  title={Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.},
  author={Harald Herrmann and Irina Sadovnik and Sabine Cerny-Reiterer and Thomas R{\"u}licke and Gabriele Stefanzl and Michael Willmann and Gregor Hoermann and Martin H Bilban and Katharina Blatt and Susanne Herndlhofer and Matthias Mayerhofer and Berthold Streubel and Wolfgang R Sperr and Tessa L Holyoake and Christine Mannhalter and Peter Valent},
  volume={123 25},
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and the extramedullary spread of leukemic SC (LSC) in CML. We have identified the cytokine-targeting surface enzyme dipeptidylpeptidase-IV (DPPIV/CD26) as a novel, specific and pathogenetically relevant biomarker of CD34(+)/CD38(─) CML LSC. In… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 48 extracted citations


Publications referenced by this paper.
Showing 1-10 of 50 references

The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D341/CD381 and CD341/CD38- AML BLOOD, 19 JUNE 2014 x VOLUME 123, NUMBER 25 EXPRESSION OF DPPIV/CD26 ON CML LSC

  • H Herrmann, M Kneidinger, S Cerny-Reiterer
  • For personal use only. on September
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…